Meningioma - Pipeline Insight, 2024

This “Meningioma - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Meningioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Meningioma Understanding

Meningioma: Overview

Meningioma is the most common intracranial tumor that originate from arachnoid cap cells present within the web -like membrane of the protective layer (meninges) covering the brain and spinal cord. Most meningiomas grow very slowly, often over many years without causing any symptoms. However, when grown to a considerable size can squeeze or compress the brain tissues, nerves, and vessels causing serious disability. According to WHO classification, based on the histology 15 variations of meningioma are recognized under 3 different grades depending on their growth rate, and likelihood of recurrence. Meningiomas are most common among women than men and often occur at older age. Although the main cause for meningioma is still unknown to the researchers but the two risk factors associated with meningioma are radiation exposure, and genetic disorder neurofibromatosis type II.

Symptoms
Symptoms can include headaches, seizures, hearing loss, blurred vision, language difficulty, memory loss, loss of smell, and weakness in muscle of arms and legs.

Diagnosis
To diagnose meningiomas, neurosurgeons often recommend sophisticated imaging techniques such as CT scan, and MRI. In some cases, biopsy may be needed to rule out other tumors and confirm meningioma diagnosis.

Treatment
Treatment for meningioma depends on the size and location of the tumor as well as on the aggressiveness of the tumor. Most of the meningiomas progress slowly and are not diagnosed during the patient’s lifetime and do not require treatment. However, when the symptoms are visible surgeons recommend surgery. If meningiomas are not removed by surgery then radiation therapy is used to reduce the chances for recurrence. Chemotherapy is not widely used for the treatment of meningiomas but clinical trials and interventional developments are carried out to study the molecular targeted approaches.

Meningioma Emerging Drugs Chapters

This segment of the Meningioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Meningioma Emerging Drugs

Gleolan: NX Devolopment Corp NX development corp.’s drug, Gleolan also known as Aminolevulinic acid is an orally administered small molecule in development for the treatment and real time detection of meningioma. Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The exogenous application of ALA leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light. It is a photosensitizer molecule which can utilize the energy to induce photochemical reactions to produce lethal toxic agents; ultimately results in cell death and tissuedestruction.

Nivolumab: Bristol-Myers Squibb Bristol-Myers Squibb “breakthrough” drug nivolumab is currently being evaluated for the treatment of Meningioma and has demonstrated good safety and efficacy profile in phase II trials. Nivolumab is a human immunoglobin (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks the interaction with PD-L1 and PD-L2, releasing anti-tumorresponse.

Meningioma: Therapeutic Assessment

This segment of the report provides insights about the different Meningioma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Meningioma

There are approx. 10+ key companies which are developing the therapies for Meningioma. The companies which have their Meningioma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, NX Devolopment Corp and others.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Meningioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Meningioma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Meningioma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Meningioma drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Meningioma R&D. The therapies under development are focused on novel approaches to treat/improve Meningioma.

Meningioma Report Insights

• Meningioma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Meningioma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Meningioma drugs?
• How many Meningioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Meningioma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Meningioma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Meningioma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• NX Development Corp.
• Clarity Pharmaceutical Ltd.
• Bristol-Myers Squibb
• Biosynthema, Inc.

Key Products

• Nivolumab
• Gleolan
• Ipilimumab
• 64- Cu Sartate & 67-Cu Sartate
• Lutetium -177 oxodotreotide

This product will be delivered within 2 business days.